Medpace Holdings vs Qiagen
Medpace Holdings is the larger business, with $2.53bn of revenue in fiscal 2025 against $2.09bn for Qiagen (1.2 times as much). Medpace Holdings grew faster (20.0% against 5.7%). Qiagen kept more of each dollar of sales as profit: a net margin of 20.3% against 17.8%. Medpace Holdings carries less debt relative to equity (0.0% against 43.8%).
| Latest fiscal year | Medpace HoldingsMEDP, 2025 | QiagenQGEN, 2025 |
|---|---|---|
| Revenue | $2.53bn | $2.09bn |
| Revenue growth | 20.0% | 5.7% |
| Net income | $451m | $425m |
| Operating margin | 21.1% | 22.3% |
| Net margin | 17.8% | 20.3% |
| Return on equity | 70.2% | 11.6% |
| Free cash flow | $682m | $453m |
| Cash | $497m | $839m |
| Total debt | $0 | $1.65bn |
| Debt to equity | 0.0% | 43.8% |
| Dividend per share | — | — |
| Dividend yield | — | 0.5% |
| Share buybacks | $917m | $280m |
| Employees | 6,200 | — |
| Market value | $18.66bn | $11.03bn |
| Price vs our value range | Below our value range | Above our value range |
| Moat score | 89 (Strong) | 58 (Moderate) |
| Insider trades, 12 months | 0 buys, 56 sales | 0 buys, 0 sales |